軟部肉腫(STS)の疫学予測(~2028)

◆英語タイトル:Soft Tissue Sarcoma (STS) Epidemiology Forecast-2028
◆商品コード:DATA00109017
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2019年12月
◆ページ数:116
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD3,250 ⇒換算¥373,750見積依頼/購入/質問フォーム
Global Site License(法人閲覧用)USD9,750 ⇒換算¥1,121,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Soft Tissue Sarcoma (STS) Epidemiology Forecast-2028
DelveInsight’s ‘Soft Tissue Sarcoma (STS) Epidemiology Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends of STS in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

According to the World Health Organization (WHO), there are more than 50 histologic subtypes of STSs. The signs and symptoms of STSs vary greatly from patients to patients based on the type of STS. However, it is not associated with any noticeable symptoms early in the course of the disease but the affected individuals may notice slow-growing, painless mass in the affected area.

According to DelveInsight’s, STS have various subtypes. It was observed that in the United States and European countries, liposarcoma and leiomyosarcoma were the most incident subtypes of STS, which contributed to majority of the cases. Whereas in Japan, subtypes, fibroblastic sarcomas and liposarcoma were more common.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2028

Soft Tissue Sarcoma (STS) – Disease Understanding

Soft-tissue sarcoma (STS) are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They also appear in the stomach and intestines (GIST) as well as behind the abdomen (retroperitoneal sarcomas) and the female reproductive system (gynecological sarcomas). STSs may be classified according to the involved cell-type, the specific nature of the malignancy, and the disease’s clinical course.

Soft Tissue Sarcoma (STS) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incident Cases of Soft Tissue Sarcoma (STS) in the 7MM, Type-specific Incidence Cases of Soft Tissue Sarcoma (STS) in the 7MM, Total Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States, Total Incident Cases of STS including GIST in the United States and Incidence of STS by Extremities (%) in the 7MM scenario of STS in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2028.

According to DelveInsight’s, the total incident population of Soft Tissue Sarcoma (STS) in seven major markets was 40,155 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2028).

Among all the seven major markets, United States accounts for highest number of cases of STS. In 2017, there were 12,390 incident cases of STS—which did not included GIST cases—in the United States. The total incident cases of GIST which were observed in the United States in 2017 accounted for 5,090. This lead to the total incident population of STS to 17,480 in 2017.

In the European countries, GIST cases are not included in the STS population. Germany had the highest incident population of STS with 4,781 cases, followed by Italy which had incident population of 4,082 in 2017. On the other hand, Spain had the lowest incident population of 2,445 in 2017.

Soft Tissue Sarcoma (STS) Report Insights

• The report covers a descriptive overview of the Soft Tissue Sarcoma (STS), explaining its causes, risk factors, pathophysiology, and diagnosis.
• Comprehensive insight has been provided into the epidemiology of Soft Tissue Sarcoma (STS) in the 7MM countries covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• Assesses growth opportunities in 7MM countries with respect to the patient population.

Soft Tissue Sarcoma (STS): Report Key Strengths

• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation by Total incident cases of STS
• Total Incident Cases of GIST in the US
• Stage-specific Incident cases of STS
• Incidence of STS by Extremities (%)

Key Benefits

• Key assessments
• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by Severity

【レポートの目次】

1. Key Insights
2. Soft-Tissue Sarcomas (STS) Patient Overview at a Glance
2.1. Patient Share (%) Distribution of Soft-Tissue Sarcomas (STS) in 2017
2.2. Patient Share (%) Distribution of Soft-Tissue Sarcomas (STS) in 2028
3. Soft-Tissue Sarcomas (STS): Disease Background and Overview
3.1. Introduction
3.2. Types of Soft-Tissue Sarcomas (STS)
3.3. The Molecular Biology of Soft-Tissue Sarcomas (STS)
3.4. Stages of Soft-Tissue Sarcomas (STS)
3.5. Diagnosis of Soft-Tissue Sarcomas (STS)
3.5.1. Medical History and Physical Exam
3.5.2. Imaging Tests
3.5.3. Biopsy
3.5.4. Pathological diagnosis of soft tissue sarcomas
3.5.5. Proposed Diagnostic Guidelines
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Incident Patient Population of Soft Tissue Sarcoma (STS)
5. Country Wise-Epidemiology of Soft Tissue Sarcoma (STS)
5.1. United States Epidemiology
5.1.1. Assumptions and Rationale
5.1.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in the United States
5.1.3. Type-Specific Incidence of STS in the United States
5.1.4. Total Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States
5.1.5. Total Incident Cases of STS including GIST in the United States
5.1.6. Incidence of STS by Extremities (%) in the United States
5.2. EU5 Epidemiology
5.2.1. Germany
5.2.1.1. Assumptions and Rationale
5.2.1.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Germany
5.2.1.3. Gender-Specific Incidence of STS in Germany
5.2.1.4. Type-Specific Incidence of STS in Germany
5.2.1.5. Age-Specific Incidence of STS in Germany
5.2.1.6. Stage-Specific Incidence of STS in Germany
5.2.1.7. Incidence of STS by Extremities (%) in Germany
5.2.2. France
5.2.2.1. Assumptions and Rationale
5.2.2.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in France
5.2.2.3. Gender-Specific Incidence of STS in France
5.2.2.4. Type-Specific Incidence of STS in France
5.2.2.5. Age-Specific Incidence of STS in France
5.2.2.6. Stage-Specific Diagnosed Incidence of STS in France
5.2.2.7. Incidence of STS by Extremities (%) in France
5.2.3. Italy
5.2.3.1. Assumptions and Rationale
5.2.3.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Italy
5.2.3.3. Gender-Specific Incidence of STS in Italy
5.2.3.4. Type-Specific Incidence of STS in Italy
5.2.3.5. Age-Specific Incidence of STS in Italy
5.2.3.6. Stage-Specific Diagnosed Incidence of STS in Italy
5.2.3.7. Incident of STS by Extremities (%) in Italy
5.2.4. Spain
5.2.4.1. Assumptions and Rationale
5.2.4.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Spain
5.2.4.3. Gender-Specific Incidence of STS in Spain
5.2.4.4. Type-Specific Incidence of STS in Spain
5.2.4.5. Age-Specific Incidence of STS in Spain
5.2.4.6. Stage-Specific Incidence of STS in Spain
5.2.4.7. Incident of STS by Extremities (%) in Spain
5.2.5. United Kingdom
5.2.5.1. Assumptions and Rationale
5.2.5.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in the United Kingdom
5.2.5.3. Gender-Specific Incidence of STS in the United Kingdom
5.2.5.4. Type-Specific Incidence of STS in the United Kingdom
5.2.5.5. Age-Specific Incidence of STS in the United Kingdom
5.2.5.6. Stage-Specific Diagnosed Incidence of STS in the United Kingdom
5.2.5.7. Incident of STS by Extremities (%) in the United Kingdom
5.3. Japan Epidemiology
5.3.1. Assumptions and Rationale
5.3.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Japan
5.3.3. Gender-Specific Incidence of STS in Japan
5.3.4. Type-Specific Incidence of STS in Japan
5.3.5. Age-Specific Incidence of STS in Japan
5.3.6. Stage-Specific Incidence of STS in Japan
5.3.7. Incident of STS by Extremities (%) in Japan
6. Appendix
6.1. Report Methodology
7. DelveInsight Capabilities
8. Disclaimer
9. About DelveInsight
Table 1 The IGF System in Sarcoma Pathogenesis
Table 2 Trunk and Extremities Sarcoma Stages
Table 3 Incident Patient Population of STS in the 7MM (2017–2028)
Table 4 Total Incident Population of STS in the United States (2017–2028)
Table 5 Type-Specific Incidence of STS in the US (2017-2028)
Table 6 Total Incident Population of GIST in the United States (2017–2028)
Table 7 Total Incident Population of STS including GIST in the United States (2017–2028)
Table 8 Gender-Specific Incidence of STS in the United States (2017–2028)
Table 9 Age-Specific Incidence of STS in the United States (2017-2028)
Table 10 Stage-Specific Incidence of STS in the United States (2017-2028)
Table 11 Incidence of STS* by Extremities (%) in the United States (2017–2028)
Table 12 Total Incident Population of STS in Germany (2017–2028)
Table 13 Gender-Specific Incidence of STS in Germany (2017–2028)
Table 14 Type-Specific Incidence of STS in Germany (2017-2028)
Table 15 Age-Specific Incidence of STS in Germany (2017-2028)
Table 16 Stage-Specific Incidence of STS in Germany (2017-2028)
Table 17 Incidence of STS by Extremities (%) in Germany (2017–2028)
Table 18 Total Incident Population of STS in France (2017–2028)
Table 19 Gender-Specific Incidence of STS in France (2017–2028)
Table 20 Type-Specific Incidence of STS in France (2017-2028)
Table 21 Age-Specific Incidence of STS in France (2017-2028)
Table 22 Stage-Specific Incidence of STS in France (2017-2028)
Table 23 Incidence of STS by Extremities (%) in France (2017–2028)
Table 24 Total Incident Population of STS in Italy (2017–2028)
Table 25 Gender-Specific Incidence of STS in Italy (2017–2028)
Table 26 Type-Specific Incidence of STS in Italy (2017-2028)
Table 27 Age-Specific Incidence of STS in Italy (2017-2028)
Table 28 Stage-Specific Incidence of STS in Italy (2017-2028)
Table 29 Incident of STS by Extremities (%) in Italy (2017–2028)
Table 30 Total Incident Population of STS in Spain (2017–2028)
Table 31 Gender-Specific Incidence of STS in Spain (2017–2028)
Table 32 Type-Specific Incidence of STS in Spain (2017-2028)
Table 33 Age-Specific Incidence of STS in Spain (2017-2028)
Table 34 Stage-Specific Incidence of STS in Spain (2017-2028)
Table 35 Incident of STS by Extremities (%) in Spain (2017–2028)
Table 36 Total Incident Population of STS in the United Kingdom (2017–2028)
Table 37 Gender-Specific Incidence of STS in the United Kingdom (2017–2028)
Table 38 Type-Specific Incidence of STS in the UK (2017-2028)
Table 39 Age-Specific Incidence of STS in the United Kingdom (2017-2028)
Table 40 Stage-Specific Incidence of STS in the United Kingdom (2017-2028)
Table 41 Incident of STS by Extremities (%) in the United Kingdom (2017–2028)
Table 42 Total Incident Population of STS in Japan (2017–2028)
Table 43 Gender-Specific Incidence of STS in Japan (2017–2028)
Table 44 Type-Specific Incidence of STS in Japan (2017-2028)
Table 45 Age-Specific Incidence of STS in Japan (2017-2028)
Table 46 Stage-Specific Incidence of STS in Japan (2017-2028)
Table 47 Incident of STS by Extremities (%) in Japan (2017–2028)
Figure 1 Common Types of Soft-Tissue Sarcomas (STS)
Figure 2 Angiosarcoma
Figure 3 Dermatofibrosarcoma protuberans (DFSP)
Figure 4 Several Growth Factor Signals Activate Cell Membrane Receptor Tyrosine Kinases Leading to Activation of Downstream Interacting Signal Transduction Pathways (PI3K/AKT, RAF/MAPK, and mTOR)
Figure 5 Grade Numbers of Soft-Tissue Sarcoma (STS)
Figure 6 Diagnosis of Soft-Tissue Sarcoma
Figure 7 Imaging Tests for Soft-Tissue Sarcoma (STS)
Figure 8 Incidence of STS in the 7MM (2017-2028)
Figure 9 Total Incident Cases of STS in the United States (2017-2028)
Figure 10 Type-Specific Incidence of STS in the United States (2017-2028)
Figure 11 Total Incident Cases of GIST in the United States (2017-2028)
Figure 12 Total Incident Cases of STS including GIST in the United States (2017-2028)
Figure 13 Gender-Specific Incidence of STS in the United States (2017-2028)
Figure 14 Age-Specific Incidence of STS in the United States (2017-2028)
Figure 15 Stage-Specific Incidence of STS in the United States (2017-2028)
Figure 16 Incidence of STS* by Extremities (%) in the United States (2017-2028)
Figure 17 Total Incident Cases of STS in Germany (2017-2028)
Figure 18 Gender-Specific Incidence of STS in Germany (2017–2028)
Figure 19 Type-Specific Incident of STS in Germany (2017-2028)
Figure 20 Age-Specific Incidence of STS in Germany (2017-2028)
Figure 21 Stage-Specific Incidence of STS in Germany (2017-2028)
Figure 22 Incidence of STS by Extremities (%) in Germany (2017-2028)
Figure 23 Total Incident Cases of STS in France (2017-2028)
Figure 24 Gender-Specific Incidence of STS in France (2017-2028)
Figure 25 Type-Specific Incident of STS in France (2017-2028)
Figure 26 Age-Specific Incidence of STS in France (2017-2028)
Figure 27 Stage-Specific of STS in France (2017-2028)
Figure 28 Incidence of STS by Extremities (%) in France (2017-2028)
Figure 29 Total Incident Cases of STS in Italy (2017-2028)
Figure 30 Gender-Specific Incidence of STS in Italy (2017-2028)
Figure 31 Type-Specific Incident of STS in Italy (2017-2028)
Figure 32 Age-Specific Incidence of STS in Italy (2017-2028)
Figure 33 Stage-Specific Incidence of STS in Italy (2017-2028)
Figure 34 Incident of STS by Extremities (%) in Italy (2017-2028)
Figure 35 Total Incident Cases of STS in Spain (2017-2028)
Figure 36 Gender-Specific Incidence of STS in Spain (2017-2028)
Figure 37 Type-Specific Incident of STS in Spain (2017-2028)
Figure 38 Age-Specific Incidence of STS in Spain (2017-2028)
Figure 39 Stage-Specific Incidence of STS in Spain (2017-2028)
Figure 40 Incident of STS by Extremities (%) in Spain (2017-2028)
Figure 41 Total Incident Cases of STS in the United Kingdom (2017-2028)
Figure 42 Gender-Specific Incidence of STS in the United Kingdom (2017-2028)
Figure 43 Type-Specific Incident of STS in the United Kingdom (2017-2028)
Figure 44 Age-Specific Incidence of STS in the United Kingdom (2017-2028)
Figure 45 Stage-Specific Incidence of STS in the United Kingdom (2017-2028)
Figure 46 Incident of STS by Extremities (%) in the United Kingdom (2017-2028)
Figure 47 Total Incident Cases of STS in Japan (2017-2028)
Figure 48 Gender-Specific Incidence of STS in Japan (2017-2028)
Figure 49 Type-Specific Incident of STS in Japan (2017-2028)
Figure 50 Age-Specific Incidence of STS in Japan (2017-2028)
Figure 51 Stage-Specific Incidence of STS in Japan (2017-2028)
Figure 52 Incident of STS by Extremities (%) in Japan (2017-2028)



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[軟部肉腫(STS)の疫学予測(~2028)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆